Cue Biopharma is trading 5.7% up at $29.00 before the September 29, 2026 session; no specific cause has been established. - The latest major company news remains positive September 20 Phase 2 CUE-221 results, which preceded the recent pullback and do not clearly explain the pre-market rise. - Broader conditions are mixed, with major indices near flat in the supplied market context; the gain cannot be confidently attributed to a market-wide move.